Drugs / cyproterone acetate
cyproterone acetate
also known as
Androcur · Androcur 10 · BAY94-8367 · Ciproterona · CPA · CPTR · Cyprostat · cyproterone · +4 more
Small molecule targets AR, NR3C1, PGR via inhibition / activation
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00196339 | Jun 2005 → Jan 2008 | prostate cancer | Duramed Research | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00955058 | Feb 2007 | polycystic ovary syndrome | Shahid Beheshti University | Unknown | No outcome recorded |
| Phase 36 trials · 2 met primary | ||||||
| Phase 3 | NCT07714616 | May 2027 → May 2029 expected | — | Eurofarma Laboratorios S.A. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01011751 | Apr 2004 → Dec 2007 | prostate adenocarcinoma | Takeda | Completed | Met primary |
| Phase 3 | NCT00280657 | Mar 2004 → May 2005 | acne | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00363285 | Jan 2003 → ? | prostate cancer | St. Bartholomew's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00005623 | Dec 1999 → Jan 2004 | prostate cancer | Barr Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00849082 | May 1987 → Nov 1995 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Met primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT02715232 | Feb 2017 → Dec 2020 | body integrity dysphoria | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT02027337 | Dec 2013 → Mar 2015 | menstrual disorder, polycystic ovary syndrome | Tyumen State Medical Academy | Unknown | No outcome recorded |
| Phase 4 | NCT01103518 | Dec 2009 → Nov 2010 | amenorrhea, dysmenorrhea | Fundação Educacional Serra dos Órgãos | Unknown | No outcome recorded |
| Phase 4 | NCT00428311 | Apr 2004 → Oct 2006 | polycystic ovary syndrome | Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04831151 | Mar 2021 → Mar 2023 | polycystic ovary syndrome | Inonu University | Unknown | No outcome recorded |
| — | NCT03043924 | Sep 2017 → Apr 2022 | polycystic ovary syndrome | University Hospital, Lille | Completed | No outcome recorded |
| — | NCT01573377 | Feb 2012 → Feb 2013 | polycystic ovary syndrome | Chongqing Medical University | Completed | No outcome recorded |
| Comparator or background therapy17 trials | ||||||
| Phase 0 | NCT04848181 Comparator | Jul 2019 → Jul 2020 | benign prostatic hyperplasia | Benha University | Completed | No outcome recorded |
| Phase 0 | NCT02689843 Comparator | Feb → Nov 2018 | polycystic ovary syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT07115082 Background | Oct 2024 → Dec 2025 overdue | primary ovarian failure | Yan Hongli | Recruiting | No outcome recorded |
| Phase 2 | NCT02729545 Comparator | Apr 2016 → Mar 2018 | polycystic ovary syndrome | Beijing Hospital of Integrated Traditional Chinese and Western Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT01933204 Comparator | Sep 2013 → Aug 2015 | — | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01973816 Background | Sep 2014 → Oct 2022 | endometriosis | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 3 | NCT00601276 Comparator | Dec 2007 → Jun 2009 | pedophilia | French National Institute of Health and Medical Research | Terminated | No outcome recorded |
| Phase 3 | NCT00003653 Comparator | Jan 1999 → Oct 2010 | prostate cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 4 | NCT03236740 Comparator | Aug 2017 → Mar 2018 | polycystic ovary syndrome | S.C.B. Medical College and Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02866786 Comparator | Aug 2016 → Apr 2017 | polycystic ovary syndrome | S.C.B. Medical College and Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01798875 Comparator | Apr 2012 → Dec 2015 | polycystic ovary syndrome | Medical University of Gdansk | Unknown | No outcome recorded |
| Phase 4 | NCT01065220 Background | Feb 2010 → Jan 2014 | — | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT07513480 Background | Aug 2024 → Nov 2025 | polycystic ovary syndrome | Mst.Sumyara Khatun | Completed | No outcome recorded |
| — | NCT07145281 Comparator | Nov 2022 → Nov 2024 | coagulation protein disease, vascular hemostatic disease | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT04590417 Background | Jan 2022 → Jan 2024 overdue | — | Thai Red Cross AIDS Research Centre | Active not recruiting | No outcome recorded |
| — | NCT02744131 Comparator | May 2016 → Sep 2018 | polycystic ovary syndrome | Kar Clinic & Hospital Pvt. Ltd. | Unknown | No outcome recorded |
| — | NCT02460445 Background | Jan 2015 → Jun 2020 | cardiovascular-kidney-metabolic syndrome | Manuel Luque Ramírez | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-07 | Advanz Pharma | ADVANZ PHARMA acquires global rights to Androcur® from Bayer advanzpharma.com ↗ |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyproterone acetate | “OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21...” NCT03236740 ↗30“1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles” NCT00280657 ↗ “COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.” NCT01933204 ↗ “one group received oral contraceptive pills and the other one received cyproterone acetate combined ethinyl-estradiol(Diane) for 3 months.” NCT00955058 ↗ “Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily” NCT02689843 ↗ “The last 10 tablets contain 2 milligrams of estradiol valerate and 1 milligram of cyproterone acetate each.” NCT07115082 ↗ “oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)” NCT01798875 ↗ “Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate” NCT04831151 ↗ |
| Known as | Androcur | “Cyproterone Acetate (Androcur, BAY94-8367)” NCT07145281 ↗ |
| Known as | Androcur 10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL139835 ↗ |
| Known as | BAY94-8367 | “Cyproterone Acetate (Androcur, BAY94-8367)” NCT07145281 ↗ |
| Known as | Ciproterona | ChEMBL registry synonym — accepted as the source's own label CHEMBL139835 ↗ |
| Known as | CPA | “Participants in the active comparator arm receive cyproterone acetate (CPA) 10 mg orally, once daily, in combination with oral estradiol, for 6 months.” NCT07145281 ↗ |
| Known as | CPTR | “an antiandrogen (nilutamide [ANAN], flutamide [FLUT], bicalutamide [CDX], or cyproterone acetate [CPTR])” NCT00003653 ↗ |
| Known as | Cyprostat | ChEMBL registry synonym — accepted as the source's own label CHEMBL139835 ↗ |
| Known as | cyproterone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02027337 ↗ |
| Known as | Cyproterone 17.alpha.-acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL139835 ↗ |
| Known as | Diane | ChEMBL registry synonym — accepted as the source's own label CHEMBL139835 ↗ |
| Known as | NSC-81430 | ChEMBL registry synonym — accepted as the source's own label CHEMBL139835 ↗ |
| Known as | SH 714 | ChEMBL registry synonym — accepted as the source's own label CHEMBL139835 ↗ |
| Action | Activate | “Progesterone receptor agonist” CHEMBL139835 ↗ |
| Action | Inhibit | “cyproterone acetate may stop the adrenal glands from making androgens.” NCT00363285 ↗ |
| Modality | Small molecule | — CHEMBL139835 ↗ |
| Route | Oral | “oral antiandrogen 1-3 times daily” NCT00003653 ↗ |
| Target | AR | “Androgen Receptor antagonist” CHEMBL139835 ↗ |
| Target | NR3C1 | “Glucocorticoid receptor antagonist” CHEMBL139835 ↗ |
| Target | PGR | “Progesterone receptor agonist” CHEMBL139835 ↗ |